These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 11461175)
1. Does peripheral neuropathy allow for the clinical expression of tardive dyskinesia by unmasking central nervous system changes? El-Mallakh RS; Pant B; Caudill R; Bacani-Oropilla T Med Hypotheses; 2001 Aug; 57(2):210-5. PubMed ID: 11461175 [TBL] [Abstract][Full Text] [Related]
2. Protective effect of adenosine reuptake inhibitors in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes. Bishnoi M; Chopra K; Kulkarni SK Pharmacology; 2007; 79(3):171-83. PubMed ID: 17377417 [TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia. Matsumoto C; Shinkai T; Hori H; Ohmori O; Nakamura J Psychiatry Res; 2004 Jun; 127(1-2):1-7. PubMed ID: 15261699 [TBL] [Abstract][Full Text] [Related]
4. [Pro- and antioxidant processes in schizophrenics with tardive dyskinesia]. Gałecki P; Pietras T; Florkowki A Psychiatr Pol; 2005; 39(6):1131-41. PubMed ID: 16526180 [TBL] [Abstract][Full Text] [Related]
5. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Inada T; Koga M; Ishiguro H; Horiuchi Y; Syu A; Yoshio T; Takahashi N; Ozaki N; Arinami T Pharmacogenet Genomics; 2008 Apr; 18(4):317-23. PubMed ID: 18334916 [TBL] [Abstract][Full Text] [Related]
6. Unusual neurophysiological features in Cockayne's syndrome: a report of two cases as a contribution to diagnosis and classification. Scaioli V; D'Arrigo S; Pantaleoni C Brain Dev; 2004 Jun; 26(4):273-80. PubMed ID: 15130695 [TBL] [Abstract][Full Text] [Related]
7. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia. Lee HJ; Kang SG; Choi JE; Paik JW; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L Neuropsychobiology; 2007; 55(1):47-51. PubMed ID: 17556853 [TBL] [Abstract][Full Text] [Related]
8. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169 [TBL] [Abstract][Full Text] [Related]
10. Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients. Ulrich S; Sandmann U; Genz A Pharmacopsychiatry; 2005 Jul; 38(4):171-7. PubMed ID: 16025420 [TBL] [Abstract][Full Text] [Related]
11. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)]. Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575 [TBL] [Abstract][Full Text] [Related]
12. A distinct subgroup of chronic inflammatory demyelinating polyneuropathy with CNS demyelination and a favorable response to immunotherapy. Pineda AA; Ogata K; Osoegawa M; Murai H; Shigeto H; Yoshiura T; Tobimatsu S; Kira J J Neurol Sci; 2007 Apr; 255(1-2):1-6. PubMed ID: 17306302 [TBL] [Abstract][Full Text] [Related]
14. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients. Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765 [TBL] [Abstract][Full Text] [Related]
15. The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia. Malik P; Andersen MB; Peacock L Pharmacol Biochem Behav; 2004 Aug; 78(4):805-10. PubMed ID: 15301939 [TBL] [Abstract][Full Text] [Related]
16. Pyridoxal plasma level in schizophrenic and schizoaffective patients with and without tardive dyskinesia. Miodownik C; Meoded A; Libov I; Bersudsky Y; Sela BA; Lerner V Clin Neuropharmacol; 2008; 31(4):197-203. PubMed ID: 18670243 [TBL] [Abstract][Full Text] [Related]
17. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study. Miyaoka T; Furuya M; Yasuda H; Hayashida M; Nishida A; Inagaki T; Horiguchi J Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):761-4. PubMed ID: 18201810 [TBL] [Abstract][Full Text] [Related]
18. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia. Segman RH; Goltser T; Heresco-Levy U; Finkel B; Shalem R; Schlafman M; Yakir A; Greenberg D; Strous R; Lerner A; Shelevoy A; Lerer B Pharmacogenomics J; 2003; 3(5):277-83. PubMed ID: 14583797 [TBL] [Abstract][Full Text] [Related]